"Protein-Tyrosine Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.
- Protein-Tyrosine Kinases
- Kinases, Protein-Tyrosine
- Protein Tyrosine Kinases
- Tyrosine Kinase
- Kinase, Tyrosine
- Tyrosine Protein Kinase
- Kinase, Tyrosine Protein
- Tyrosylprotein Kinase
- Kinase, Tyrosylprotein
- Tyrosine-Specific Protein Kinase
- Kinase, Tyrosine-Specific Protein
- Protein Kinase, Tyrosine-Specific
- Tyrosine Specific Protein Kinase
- Tyrosine-Specific Protein Kinases
- Kinases, Tyrosine-Specific Protein
- Protein Kinases, Tyrosine-Specific
- Tyrosine Specific Protein Kinases
- Protein-Tyrosine Kinase
- Kinase, Protein-Tyrosine
- Protein Tyrosine Kinase
- Tyrosine Protein Kinases
- Kinases, Tyrosine Protein
- Protein Kinases, Tyrosine
Below are MeSH descriptors whose meaning is more general than "Protein-Tyrosine Kinases".
Below are MeSH descriptors whose meaning is more specific than "Protein-Tyrosine Kinases".
This graph shows the total number of publications written about "Protein-Tyrosine Kinases" by people in this website by year, and whether "Protein-Tyrosine Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Protein-Tyrosine Kinases" by people in Profiles.
Frequent expression of a novel cancer testis antigen, protein kinase human monopolar spindle 1 (hMps1/TTK) in human urinary bladder transitional cell carcinoma. Drug Discov Ther. 2021 Sep 22; 15(4):204-209.
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2021 07 15; 27(14):3834-3844.
Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis. Target Oncol. 2020 10; 15(5):589-598.
Pharmacophore-based designing of putative ROS-1 targeting agents for NSCLC. Mol Divers. 2021 May; 25(2):1091-1102.
In the Era of BCR-ABL1 Inhibitors, Are We Closing the Survival Gap Between Allogeneic Hematopoietic Cell Transplantation and Chemotherapy for Philadelphia Chromosome-Positive?Acute Lymphoblastic Leukemia in First Complete Remission? Biol Blood Marrow Transplant. 2018 04; 24(4):637-638.
Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries. Cancer Med. 2016 08; 5(8):1883-9.
Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options. J Surg Oncol. 2016 Jan; 113(1):55-61.
Renal involvement in lupus is characterized by unique DNA methylation changes in naïve CD4+ T cells. J Autoimmun. 2015 Jul; 61:29-35.
Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. Clin Cancer Res. 2015 May 01; 21(9):2115-26.
Casein kinase 1d-dependent Wee1 protein degradation. J Biol Chem. 2014 Jul 04; 289(27):18893-903.